Hyderabad-based biologicals company Indian Immunologicals Limited (IIL)'s wholly-owned subsidiary Pristine Biologicals (NZ) Limited (PBL) on Monday inaugurated its new 'bovine serum' manufacturing facility in New Zealand.
The objective of the investment was to gain control over the supplies of a key ingredient used in vaccine manufacture. Serum from New Zealand is highly regarded as the country is free from several diseases listed by the World Organisation for Animal Health (OIE). The new plant can manufacture up to 300 tonnes of serum, IIL said in a release.
At the new plant, bovine blood will be collected only from EU and USDA-approved abattoirs in closed-method under hygienic conditions. The plant will produce key products like new-born calf serum, adult bovine serum (NZ origin) and bulk bovine haemoglobin (NZ origin) for biopharmaceutical, research and diagnostic purpose, the company said.
